[O7] Oral Session 7　Gastrointestinal Cancer 2（Lower GI Tract-Colorectal Cancer 1）
【E】

[O7-4] Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to 1st-line treatment with anti-EGFR antibody: JACCRO CC-16

^○Tamotsu Sagawa¹, Akihito Tsuji², Hironaga Satake³, Masato Nakamura⁴, Yu Sunakawa⁵, Shotaro Korehisa⁶, Masato Matsuura⁷, Yasuhiro Yuasa⁸, Takashi Mine⁹, Hiroaki Nagano¹⁰, Kunitoshi Shigeyasu¹¹, Tatsuya Kinjo¹², Masahito Kotaka¹³, Hiroyuki Okuyama², Yutaro Kubota¹⁴, Mitsugu Kochi¹⁵, Toshiki Masuishi¹⁶, Masahiro Takeuchi¹⁷, Wataru Ichikawa¹⁸, Masashi Fujii¹⁹ (1.Division of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, 2.Department of Clinical Oncology, Faculty of Medicine, Kagawa University, 3.Department of Medical Oncology, Kobe City Medical Center General Hospital, 4.Aizawa Comprehensive Cancer Center, Aizawa Hospital, 5.Department of Clinical Oncology, St. Marianna University School of Medicine, 6.Department of Surgery, National Hospital Organization Fukuoka-higashi Medical Center, 7.Department of Surgery, Kobe City Nishi-Kobe Medical Center, 8.Department of Gastrointestinal Surgery, Tokushima Red Cross Hospital, 9.Department of Clinical Oncology, Nagasaki Harbor Medical Center, 10.Department of Gastroenterological, Breast and Endocrine Surgery, 11.Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 12.Division of Digestive and General Surgery, University of the Ryukyus, 13.Gastrointestinal Cancer Center, Sano Hospital, 14.Department of Clinical Oncology, Showa University Hospital, 15.Department of Digestive Surgery, Nihon University Itabashi Hospital, 16.Department of Clinical Oncology, Aichi Cancer Center Hospital, 17.Graduate School of Mathematical Sciences, The University of Tokyo, 18.Division of Medical Oncology, Showa University Fujigaoka Hospital, 19.Department of Digestive Surgery, Nihon University School of Medicine)